Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Observation Letter
ARTICLE IN PRESS
doi:
10.25259/IJDVL_898_2024

Paradoxical eczema in psoriasis patients following treatment with secukinumab

Department of Dermatology, Base Hospital, Lucknow, Uttar Pradesh, India

Corresponding author: Dr. Shekhar Neema, Department of Dermatology, Base Hospital, Lucknow, Uttar Pradesh, India. shekharadvait@gmail.com

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Neema S, Pathania V, Nyalam P, Kamboj P, GB P. Paradoxical eczema in psoriasis patients following treatment with secukinumab. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL_898_2024

Dear Editor,

Psoriasis is a chronic immune-mediated inflammatory disease of unknown aetiology, with various biological therapies approved for its management. These biologics include TNF α inhibitors (etanercept, adalimumab, infliximab and certolizumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab), IL-12/23 inhibitors (ustekinumab) and IL-23 inhibitors (guselkumab, tildrakizumab and risankizumab). Secukinumab, an IL-17 inhibitor, was the first in class, approved in 2015 for treating moderate to severe chronic plaque psoriasis.1 Although the side effects are uncommon, the most frequently reported include nasopharyngitis and headache.2,3 Cutaneous adverse events (CAE) reported during biologic therapies include skin infections, paradoxical psoriasis, pustular dermatoses, and eczema.4 In this respect, we describe three cases of paradoxical eczema in psoriasis patients after secukinumab administration. The case details are tabulated in Table 1.

Table 1: Case Details
Sr No Age/Duration (years) Treatment history Atopy Eczema
Treatment
Interval after starting secukinumab Site
Case 1 63/7

MTX

CsA

Acitretin

Nil 2 weeks Trunk

Prednisolone 30 mg OD

CsA 5mg/Kg

Secukinumab stopped

Case 2 49/12

MTX

Etanercept

Nil 3 weeks Scrotum Topical steroid and emollient
Case 3 65/25

MTX

CsA

Acitretin

Etanercept

Infliximab

Nil 12 weeks Legs

CsA 5 mg/Kg

Secukinumab stopped

MTX - methotrexate; OD - daily; CsA – cyclosporine

The first case includes a 63-year-old man with a seven-year history of chronic plaque psoriasis, presenting with a recent flare affecting 60% of the body surface area (BSA). He was treated intermittently with methotrexate, cyclosporine, and acitretin in the last seven years. Treatment with injection secukinumab was initiated at a dose of 300 mg subcutaneously weekly. However, after two weeks, there was an aggravation of symptoms with oozing and involvement of 80% BSA. A histopathological examination revealed spongiotic dermatitis [Figure 1]. Secukinumab was discontinued, and the patient was managed with a tapering course of oral steroids (prednisolone started at 30 mg once a day and tapered slowly over 4 weeks) and cyclosporine (5 mg/kg). Significant improvement was observed at four weeks.

Diffuse erythematous scaly plaques with excoriations on the trunk.
Figure 1:
Diffuse erythematous scaly plaques with excoriations on the trunk.

The second case involved a 49-year-old man with a 12-year history of chronic plaque psoriasis and psoriatic arthritis. He presented with a recent disease flare affecting 70% of the body surface area. He was previously treated with methotrexate and etanercept. Injection secukinumab (300 mg, subcutaneously, weekly) was started, leading to significant improvement in skin and joint symptoms after three weeks. However, the patient developed scrotal dermatitis [Figure 2]. He was treated with emollients twice a day and topical fluticasone 0.05% cream once a day. His symptoms resolved and Secukinumab was continued as per standard dosing protocol.

Erythematous oozy plaques on the scrotum.
Figure 2:
Erythematous oozy plaques on the scrotum.

The third case includes a 65-year-old man with a 25-year history of chronic plaque psoriasis with psoriatic arthritis. He presented with active disease and a recent flare affecting 25% of the body surface area. He was treated previously with methotrexate, cyclosporine, etanercept, infliximab, and acitretin. Secukinumab 300 mg subcutaneously, administered weekly, was initiated for the flare, resulting in significant improvement in both skin and joint disease. However, after three months, the patient developed eczematous eruptions with oozing on both legs [Figure 3]. Cyclosporine at 5 mg/kg was started but without much improvement at 2 weeks. Secukinumab was discontinued, leading to an improvement in eczema after two weeks.

Erythematous oozy crusted plaques involving the lower half right leg.
Figure 3:
Erythematous oozy crusted plaques involving the lower half right leg.

The use of biological therapies for psoriasis has been associated with the development of eczema, among other cutaneous adverse events.4 Development of eczema while on anti-TNFα therapy has been well-documented in the literature.5 However, there are only anecdotal cases of eczematous eruptions induced by anti-IL-17 agents in patients with psoriasis.6 The co-occurrence of psoriasis and eczema is rare but has been reported occasionally.7,8

Multiple hypotheses have been described in the literature for developing paradoxical eczema (PE) during biological therapy. The PE may be due to an imbalance in Th1 and Th2 pathways. The inhibition of the Th1/Th17 pathway by secukinumab may exacerbate the Th2 pathway and the consequent appearance of atopic eczema.2,3,6 “Immune or cytokine imbalance syndromes” could also explain the occurrence of eczema on biologics.4 Despite atopic eczema and psoriasis being genetically and immunologically discrete, biological therapy for either condition can lead to a paradoxical phenotypic switch to the other due to cytokine imbalance.8 Eczematous eruption induced by anti-TNF-α agents showed high levels of IL-22. Therefore, IL-22 may be a key mediator in the pathogenesis of eczema induced by anti-IL-17 agents.6

A personal history of atopy could also be a risk factor for paradoxical eczema. Studies have shown that patients with a prior history of atopy may experience eczematous eruptions caused by biologics.4,8 However, no epidemiological studies have confirmed an association between PE and atopy in psoriasis patients.8 If a paradoxical reaction is severe, secukinumab should be discontinued, and an alternative treatment for psoriasis and eczema should be initiated. Mild reactions can be managed with topical steroids, and secukinumab can be continued. It is important to be aware of this rare adverse event with IL-17 inhibitors, which can be misconstrued as a primary or secondary failure. Since IL-17 inhibitors are not used to treat eczema, it is better to term this condition as IL-17 triggered eczema rather than paradoxical eczema.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

References

  1. , , . Secukinumab in the treatment of psoriasis: Patient selection and perspectives. Psoriasis (Auckl). 2018;8:75-82.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  2. , , , , . Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep Dermatol. 2021;13:336-39.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , . Atopic-like dermatitis after secukinumab injection: A case report. Dermatol Ther. 2019;32:e12751.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , . Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: A systematic review. J Eur Acad Dermatol Venereol. 2020;34:1440-48.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: A review. J Dermatolog Treat. 2017;28:237-41.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , , et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: An emerging condition. Br J Dermatol. 2019;181:604-06.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , . Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin. JAAD Case Rep. 2018;4:429-33.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , . Paradoxical eczema in patients with psoriasis receiving biologics: A case series. Clin Exp Dermatol. 2022;47:1174-78.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]

Fulltext Views
1,822

PDF downloads
564
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections